Last --
Change Today 0.00 / 0.00%
Volume 0.0
2348 On Other Exchanges
Symbol
Exchange
2348 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

dawnrays pharmaceutical hold (2348) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DAWNRAYS PHARMACEUTICAL HOLD (2348)

Related News

No related news articles were found.

dawnrays pharmaceutical hold (2348) Related Businessweek News

No Related Businessweek News Found

dawnrays pharmaceutical hold (2348) Details

Dawnrays Pharmaceutical (Holdings) Limited, an investment holding company, develops, manufactures, and sells non-patented pharmaceutical medicines in Mainland China, India, and other countries. The company operates in two segments, Intermediates and Bulk Medicines, and Finished Drug. It offers cephalosporin antibiotics cover intermediates, bulk medicines, and powder for injections; and specific medicines covering therapeutic areas for anti-HBV, anti-allergic, cardiovascular system, digestive system, urinary system, and endocrine system with dosage forms of tablets, capsules, and granules. The company was founded in 1995 and is headquartered in Wanchai, Hong Kong. Dawnrays Pharmaceutical (Holdings) Limited is a subsidiary of Fortune United Group Limited.

957 Employees
Last Reported Date: 09/2/14
Founded in 1995

dawnrays pharmaceutical hold (2348) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: CNY873.0K
Co-Founder and Executive Director
Total Annual Compensation: CNY533.0K
Executive Director
Total Annual Compensation: CNY533.0K
Compensation as of Fiscal Year 2013.

dawnrays pharmaceutical hold (2348) Key Developments

Dawnrays Pharmaceutical Holdings Ltd. Announces Executive Changes, Effective March 31, 2015

Dawnrays Pharmaceutical Holdings Ltd. announced that Ms. Huang Dongmei resigned as the Chief Executive Officer with effect from 1 March 2015; and (ii) Ms. Li Kei Ling was appointed as the Chief Executive Officer with effect from 1 March 2015. Ms. Li is also an executive director and the chairman of the Board of the company.

Dawnrays Pharmaceutical Holdings Ltd. Presents at 13th Annual dbAccess China Conference, Jan-12-2015

Dawnrays Pharmaceutical Holdings Ltd. Presents at 13th Annual dbAccess China Conference, Jan-12-2015 . Venue: Grand Hyatt Hotel, Beijing, China.

Dawnrays Pharmaceutical Holdings Ltd. Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2014; Declares Interim Dividend for the Year Ending December 31, 2014

Dawnrays Pharmaceutical Holdings Ltd. reported unaudited consolidated earnings results for the six months ended June 30, 2014. For the period, the company reported profit attributable to owners of the parent was RMB 101,784,000 or RMB 0.1262 diluted earnings per share on revenue of RMB 409,884,000 against profit attributable to owners of the parent of RMB 78,223,000 or RMB 0.0975 diluted earnings per share on revenue of RMB 446,911,000 a year ago. Profit before tax was RMB 130,094,000 against RMB 97,896,000 a year ago. Net cash flows from operating activities was approximately RMB 205,401,000 compared to RMB 103,338,000 a year ago. On August 15, 2014, the company declared an interim dividend for the year ending December 31, 2014, at HKD 0.025 per share, amounting to a total sum of approximately HKD 20,154,000. The register of members of the company will be closed from September 8, 2014 to September 10, 2014 for the purposes of ascertaining entitlements to the company's interim dividend, during which period no transfer of shares will be registered.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
2348:HK $4.79 HKD -0.02

2348 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 2348.
View Industry Companies
 

Industry Analysis

2348

Industry Average

Valuation 2348 Industry Range
Price/Earnings 17.5x
Price/Sales 3.5x
Price/Book 2.7x
Price/Cash Flow 17.5x
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DAWNRAYS PHARMACEUTICAL HOLD, please visit www.dawnrays.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.